SCHEMBL3607773

SCHEMBL3607773

CC(=O)NCc1ccc(-c2csc(NC(=N)N)n2)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.68
ALDH1A1 P00352 5/20 0.68
MEN1 O00255 5/20 0.68
KDM4E B2RXH2 4/20 0.68
MAPT P10636 4/20 0.68
HSD17B10 Q99714 3/20 0.68
ABL1 P00519 4/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.51
NPC1 O15118 3/20 0.46
MAPK1 P28482 2/20 0.46
HDAC8 Q9BY41 2/20 0.45
RAB9A P51151 3/20 0.44
GAA P10253 1/20 0.44
HTT P42858 3/20 0.42
HDAC1 Q13547 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10524859 0.89 KDM4E (0.72) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL10520562 0.89 KMT2A (0.53) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL9430903 0.88 KMT2A (0.68) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL10519037 0.87 MEN1 (0.51) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL10519766 0.86 MEN1 (0.51) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL3606627 0.82 KDM4E (0.45) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL9430279 0.81 ALDH1A1 (1.00) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL10622016 0.81 HDAC8 (0.46) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL10518979 0.81 ALDH1A1 (0.67) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL3607652 0.81 KDM4E (0.44) KMT2AALDH1A1MEN1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 KMT2A 4116/4885ALDH1A1 1302/4885MEN1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.